A signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size

Yara Eid Mutlak1,2, Dina Aweida1,2, Alexandra Volodin1, Bar Ayalon1, Nitsan Dahan1, Anna Parnis1 & Shenhav Cohen1✉

Signaling through the insulin receptor governs central physiological functions related to cell growth and metabolism. Here we show by tandem native protein complex purification approach and super-resolution STED microscopy that insulin receptor activity requires association with the fundamental structural module in muscle, the dystrophin glycoprotein complex (DGC), and the desmosomal component plakoglobin (γ-catenin). The integrity of this high-molecular-mass assembly renders skeletal muscle susceptibility to insulin, because DGC-insulin receptor dissociation by plakoglobin downregulation reduces insulin signaling and causes atrophy. Furthermore, low insulin receptor activity in muscles from transgenic or fasted mice decreases plakoglobin-DGC-insulin receptor content on the plasma membrane, but not when plakoglobin is overexpressed. By masking β-dystroglycan LIR domains, plakoglobin prevents autophagic clearance of plakoglobin-DGC-insulin receptor co-assemblies and maintains their function. Our findings establish DGC as a signaling hub, and provide a possible mechanism for the insulin resistance in Duchenne Muscular Dystrophy, and for the cardiomyopathies seen with plakoglobin mutations.
The reciprocal dynamics between tissue architecture and function is maintained by the integrity of structural complexes and the transmission of growth signals from cell surface receptors. In the skeletal muscle, impaired structural integrity or loss of growth-promoting signals lead to reduced cell size and contractile capacity, and different myopathies in human7,12. Phosphoinositide 3-kinase-Akt (PI3K-Akt) signaling is transmitted via the insulin receptor, and reduced activity of this pathway causes muscle atrophy, and largely contributes to the development of insulin resistance in type 2 diabetes4,5. A similar reduction in insulin sensitivity7,8 can be seen in some Duchenne muscular dystrophy (DMD) patients, a disease caused by dissociation of dystrophin glycoprotein complex (DGC)9,10, although the precise mechanism is unknown. Specifically, it is unclear how the integrity of the pivotal structural unit of the skeletal muscle, the DGC, affects insulin-PI3K-Akt signaling. Here, we demonstrate that the DGC is physically and functionally linked to the insulin receptor on the plasma membrane.

The DGC plays a structural role by anchoring the cytoskeleton to the extracellular matrix (ECM) to provide mechanical support and protect the sarclemma against stress imposed during muscle contraction11. It is composed of dystrophin, dystroglycans, sarcolemmal plakoglobin, and syndapins2,6. A similar two-peak elution profile has been obtained from rat skeletal muscles (Supplementary Fig. 1). Plakoglobin was predominantly enriched in the high MW protein peak, and thus seems to be a component of multiprotein assemblies (Fig. 1d). In fact, analysis of the high MW protein peak by a Resource Q anion exchange column indicated that plakoglobin was eluted at a high yield together with several high MW polypeptides as a major monodisperse sharp peak at 250 mM NaCl (peak #5) (Fig. 1e, f). Mass spectrometry analysis (Fig. 1f, lane 7) identified mainly cytoskeletal (28%) and membrane-bound (55%) proteins, including components comprising costameres, such as the DGC component β-sarcoglycan, the basal lamina glycoprotein laminin, which binds to the DGC, and the dystrophin-associated protein spectrin27 (Fig. 1g, h and Supplementary Table 1). Furthermore, the major intermediate filament protein in the muscle, desmin, was identified, as well as the associated proteins desmoplakin29, the desmin-cross-linking protein α-actinin, and α-actin, a component localized to the Z-bands where desmin filaments are aligned (Supplementary Table 1).

To confirm these findings by an independent approach, and identify additional proteins that bind plakoglobin, we transfected mouse tibialis anterior (TA) muscle with a plasmid encoding 6His-plakoglobin and isolated bound proteins with a Nickel column (Fig. 2a). Mass spectrometry analysis identified most of the aforementioned components as plakoglobin-bound proteins, and additional DGC core components, including dystrophin, α-sarcoglycan, β-sarcoglycan, γ-sarcoglycan, α-syntrophin, β-syntrophin, and β-dystroglycan, the costamere marker in the skeletal muscle, vinculin, where DGC is normally located13,15, and the specialized lipid membrane domain caveolea markers, caveolin-1 and -3, which interact with DGC in striated muscle and link the cytoskeleton to the ECM30,31 (Supplementary Table 2). Other plasma membrane-bound proteins included insulin signaling components such as the p85 regulatory subunit of PI3K, which we previously showed can bind plakoglobin21, the insulin receptor substrate 1, which specifically binds to the insulin receptor and activates PI3K-Akt signaling32, two catalytic subunits of PI3K, type 3 and gamma, that bind p85-PI3K to form the PI3K complex, the insulin-like growth factor 2 receptor, and the insulin-like growth factor-binding protein (Supplementary Table 2).

Plakoglobin is a component of desmosome adhesion complexes that are prominent in tissues that must withstand mechanical stress, especially cardiomyocytes and epithelia17,18. In epithelia, plakoglobin regulates signaling pathways (e.g., by Wnt) that control cell motility19, growth, and differentiation20. We have recently shown that plakoglobin is of prime importance in regulating skeletal muscle size because it binds to the insulin receptor and enhances the activity of the PI3K-Akt pathway21. Activation of this pathway by insulin-like growth factor-1 (IGF-1) or insulin promotes glucose uptake and overall protein synthesis, and inhibits protein degradation2,22,23. In untreated diabetes, sepsis, and cancer cachexia24, impaired signaling through this pathway causes severe muscle wasting, which can be inhibited by the activation of PI3K-Akt-FoxO signaling25. Because changes in plakoglobin levels alone influence PI3K-Akt-FoxO pathway21, perturbation of its function may contribute to insulin resistance in disease. We show here that plakoglobin is important for the maintenance of muscle size by stabilizing DGC and mediating its association with and activation of the insulin receptor.

**Results**

**Isolation of plakoglobin complexes from the skeletal muscle.**

To understand plakoglobin’s role in the maintenance of normal muscle size, we isolated the complexes that it forms in skeletal muscle. Using a modified protocol26, we washed pellets from insoluble fractions of lower limb mouse muscles (the 10,000 × g pellet) with high ATP buffer to dissociate the myofibrils, and high pH buffer (pH 9 at 37 °C) to solubilize cytoskeletal and membrane-bound protein complexes (Fig. 1a, b). Ammonium sulfate precipitates were then analyzed by gel filtration column (Superdex 200 10/300), and showed two distinct protein peaks containing high and low molecular weight (MW) proteins (Fig. 1c, d). A similar two-peak elution profile has been obtained from rat skeletal muscles (Supplementary Fig. 1). Plakoglobin was predominantly enriched in the high MW protein peak, and thus seems to be a component of multiprotein assemblies (Fig. 1d). In fact, analysis of the high MW protein peak by a Resource Q anion exchange column indicated that plakoglobin was eluted at a high yield together with several high MW polypeptides as a major monodisperse sharp peak at 250 mM NaCl (peak #5) (Fig. 1e, f). Mass spectrometry analysis (Fig. 1f, lane 7) identified mainly cytoskeletal (28%) and membrane-bound (55%) proteins, including components comprising costameres, such as the DGC component β-sarcoglycan, the basal lamina glycoprotein laminin, which binds to the DGC, and the dystrophin-associated protein spectrin27 (Fig. 1g, h and Supplementary Table 1). Furthermore, the major intermediate filament protein in the muscle, desmin, was identified, as well as the associated proteins desmoplakin29, the desmin-cross-linking protein α-actinin, and α-actin, a component localized to the Z-bands where desmin filaments are aligned (Supplementary Table 1).

To confirm these findings by an independent approach, and identify additional proteins that bind plakoglobin, we transfected mouse tibialis anterior (TA) muscle with a plasmid encoding 6His-plakoglobin and isolated bound proteins with a Nickel column (Fig. 2a). Mass spectrometry analysis identified most of the aforementioned components as plakoglobin-bound proteins, and additional DGC core components, including dystrophin, α-sarcoglycan, β-sarcoglycan, γ-sarcoglycan, α-syntrophin, β-syntrophin, and β-dystroglycan, the costamere marker in the skeletal muscle, vinculin, where DGC is normally located13,15, and the specialized lipid membrane domain caveolea markers, caveolin-1 and -3, which interact with DGC in striated muscle and link the cytoskeleton to the ECM30,31 (Supplementary Table 2). Other plasma membrane-bound proteins included insulin signaling components such as the p85 regulatory subunit of PI3K, which we previously showed can bind plakoglobin21, the insulin receptor substrate 1, which specifically binds to the insulin receptor and activates PI3K-Akt signaling32, two catalytic subunits of PI3K, type 3 and gamma, that bind p85-PI3K to form the PI3K complex, the insulin-like growth factor 2 receptor, and the insulin-like growth factor-binding protein (Supplementary Table 2).

DGC, insulin receptors, and plakoglobin physically interact. To learn whether DGC, insulin receptors, and plakoglobin form one intact co-assembly, we repeated 6His-plakoglobin isolation from transfected TA muscles using a Nickel column, and eluted the bound proteins with a histidine gradient. DGC components, vinculin, caveolin-1, the insulin receptor, and laminin, were effectively co-purified with 6His-plakoglobin (Fig. 2b). These proteins physically interact in vivo at membrane caveolea because DGC components, insulin receptors, and caveolin-1 co-precipitated together with plakoglobin from the high MW protein peak (Fig. 2c, d). Moreover, plakoglobin, DGC components, desmin, insulin receptor, and p85-PI3K sedimented to the same glycerol gradient fractions (Fig. 2e), and formed a native multimeric assembly because they co-precipitated together with plakoglobin from these fractions, and also reciprocally with α-syntrophin (Fig. 2f). β-Dystroglycan appeared in its glycosylated form (Fig. 2e), which is essential for DGC stability17. Also, the presence of desmin in plakoglobin-containing precipitates is consistent with the structural role of plakoglobin in linking the desmin cytoskeleton through membrane structures (e.g., DGC) to the ECM33,34. These interactions were specific because tyrosine kinase receptor, MuSK, which was also
present in these fractions, was not precipitated with plakoglobin antibody (Fig. 2e, f and Supplementary Fig. 2). Similar interactions were demonstrated by coimmunoprecipitation in the heart and liver (Supplementary Fig. 2), indicating that these interactions are not unique to the skeletal muscle, and plakoglobin probably binds, and thus might regulate, these structural and signal transmitting modules in many (perhaps all) tissues.

Immunofluorescence staining of muscle cross-sections and analysis by confocal and super-resolution stimulated emission depletion (STED) microscopy confirmed that plakoglobin potentially colocalize with β-dystroglycan, insulin receptors (Fig. 2g), dystrophin and vinculin (Supplementary Fig. 3a) on the fiber membrane. Sub-diffraction co-occurrence analysis of STED images and three-dimensional analysis of confocal images confirmed a distinct heteromultimeric assembly of DGC-insulin receptor-plakoglobin with vinculin (Fig. 2g and Supplementary Fig. 3a, b). These interactions were corroborated by a proximity ligation assay (PLA), which allows in situ detection of protein–protein interactions. Muscle cross-sections were incubated with primary antibodies against insulin receptor and β-dystroglycan and secondary antibodies linked to complementary DNA probes. Because target proteins are 20–100 nm apart, the probes could form a closed DNA circle, which served as a template for rolling circle amplification reaction, and subsequent incorporation of fluorescently labeled nucleotides. Consequently, the red fluorescent spots along the plane of the fiber membrane indicate areas where the insulin receptor and β-dystroglycan interact (Fig. 2h). These red spots were not formed in muscle sections incubated with β-dystroglycan antibody alone (Fig. 2h). Interestingly, these discrete regions are located in close proximity to the nucleus, most likely to efficiently translate signals from the plasma membrane (e.g., PI3K-Akt signaling) to transcriptional response (Supplementary Fig. 3c). Together, these findings indicate that in the skeletal muscle, and probably other tissues, plakoglobin co-assembles with DGC and the insulin receptor on the plasma membrane, and may be important for bridging and stabilizing these structures.

Plakoglobin links insulin receptor activity to DGC integrity. To test whether plakoglobin enhances the structural integrity and functional properties of DGC and insulin receptor, we down-regulated plakoglobin in normal muscle by electroporation of short
hairpin RNA (shRNA) (shJUP)\textsuperscript{21}, and analyzed the effects on DGC stability and insulin-PI3K-Akt signaling. Glycerol gradient fractionation of purified membranes from transfected muscles showed that most proteins sedimented to the same fractions, but not when plakoglobin was downregulated (Fig. 3a). Plakoglobin loss led to decreased insulin receptor phosphorylation, and caused a marked reduction in glycosylated β-dystroglycan on the membrane, suggesting that DGC was destabilized\textsuperscript{11}. Furthermore, the content of vinculin, dystrophin, and the insulin receptor on the membrane was also reduced and their distribution was altered in shJUP-expressing

Fig. 2 Plakoglobin binds DGC components and insulin receptors at costameres on the plasma membrane. a Affinity-based purification of plakoglobin-containing complex. 6His-tagged plakoglobin encoding plasmid was electroporated into muscle, and 6His-plakoglobin-bound proteins were isolated with Nickel beads and identified by mass spectrometry. b 6His-plakoglobin-bound proteins were eluted from Nickel column with histidine gradient (50–250 mM) and analyzed by immunoblotting. Fraction #2 was subjected to mass spectrometry. Nickel beads and identiﬁcation of plakoglobin-DGC components, the insulin receptor, and desmin interact. Left: Proteins co-puriﬁcation observed by immunoblotting. MuSK did not bind plakoglobin, although it sedimented to the same fractions. Right: Reciprocal immunoprecipitation with antibody from membrane fractions isolated from normal muscle. Two experiments were performed: One with plakoglobin antibody and one with syntrophin antibody.

caveolin-1, desmin, and MuSK sediment to the same glycerol gradient fractions (marked by a red rectangle). Membrane-cytoskeleton fraction from mouse muscle was analyzed by 10–40% glycerol gradient and immunoblottting. n = two independent experiments. d Plakoglobin immunoprecipitation from the high MW protein peak. Bound proteins were detected by immunoblotting. e Plakoglobin, DGC components (including glycosylated-β-dystroglycan), the insulin receptor, caveolin-1, desmin, and MuSK interact. Left: Proteins co-puriﬁcation observed by immunoblotting. 6His-plakoglobin into ed membranes from transfected muscles showed coloration of plakoglobin-β-dystroglycan on the membrane, suggesting that DGC potentially colocalize at costameres on the skeletal muscle membrane. STED: Stimulated emission depletion microscopy. Confocal (bar, 5 μm) and STED (bar, 2 μm) images of muscle cross-sections stained with the indicated antibodies. n = three independent experiments. STED analysis was performed using the spots module of the Imaris software for the three proteins. The double and triple co-occurrence spots are presented in yellow (plakoglobin-β-dystroglycan) and blue (plakoglobin-β-dystroglycan-insulin receptor). Right: Percent colocalization of indicated proteins in region of interest (the region of co-occurrence, confocal images), and the corresponding Pearson’s correlation coefficients of colocalization. n = 3, and two independent experiments. Data are represented as mean ± SEM. b Proximity ligation assay (PLA) was performed on TA cross-sections with β-dystroglycan and insulin receptor antibodies or β-dystroglycan antibody alone. Red fluorescent dots indicate areas of β-dystroglycan-insulin receptor association.
muscles, strongly suggesting that the integrity of plakoglobin-containing complex was compromised (Fig. 3a). This reduction in the membrane content of DGC components and insulin receptor is selective because in the muscles expressing shJUP, the protein levels of caveolin-1 and the unmodified form of β-dystroglycan were similar to shLacz controls (Fig. 3a).

Consistently, glucose injection to mice to induce insulin secretion (vs. saline) (Fig. 3b), and enhanced DGC-insulin receptor association (Fig. 3c), but not in the muscles expressing shJUP, where insulin receptor and PI3K phosphorylation was markedly reduced, and much less of these proteins were associated in one intact complex (Fig. 3a–c). Similar effects were obtained in muscles expressing shJUP or shLacz from mice injected with saline (Supplementary Fig. 4a). Interestingly, the soluble pools (the fraction soluble at 6000 × g) of DGC subunits (i.e., dystrophin, β-dystroglycan, α-syntrophin) were smaller when plakoglobin was downregulated (Fig. 3d) and insulin signaling fell (Fig. 3a, b, d), possibly due to their degradation. Loss of plakoglobin and the resulting reduction in DGC integrity also enhanced depolymerization of the desmin cytoskeleton because its phosphorylated species decreased in the insoluble fraction (Fig. 3d)35–37. In fact, these effects by shJUP must
Fig. 3 Plakoglobin downregulation reduces DGC-insulin receptor association and insulin signaling, and causes atrophy. Contralateral muscles from fasted mice were electroporated with plakoglobin shRNA (shJUP) or control shRNA (shLacz). Red rectangle marks fractions containing glycosylated-β-dystroglycan in shLacz-expressing muscles. STED: Stimulated emission depletion microscopy. **a** Muscle membrane extracts were analyzed by glycerol gradients and immunoblotting. n = three independent experiments. **b** Mice were injected with saline or glucose (1 mg/g body weight) and muscle membrane extracts were analyzed by glycerol gradient and immunoblotting. n = three independent experiments. **c** Syntrophin immunoprecipitation from muscle membrane extracts from mice injected with saline or glucose (1 mg/g body weight). Precipitates were analyzed by immunoblotting. Right: Densitometric measurements of presented blots. Graph depicts ratio of each protein to syntrophin. n = two independent experiments. **d** Soluble fractions of transfected muscles from mice injected with saline or glucose were analyzed by immunoblotting. n = two independent experiments. **e** Mean weights of muscles expressing shJUP are plotted as the percentage of shLacz muscles. Data are represented as mean ± SEM. *P < 0.00005 by one-tailed t test. n = two independent experiments. **f** Cross-sectional areas of 521 fibers expressing shJUP (also express GFP, green bars) vs. 521 non-transfected fibers (black bars). n = 4 mice. **g** Top: Representative confocal images of transfected muscles cross-sections (also express GFP), stained with anti-insulin receptor and anti-β-dystroglycan. Bar, 20 μm. n = two independent experiments. Bottom: Colocalization of β-dystroglycan and insulin receptor in region of interest (the region of co-occurrence, data are presented as ratio to shLacz), and the corresponding Pearson’s correlation coefficients of colocalization. n = 8, two independent experiments. *P < 0.05 vs. shLacz, by one-tailed t test. Data are represented as mean ± SEM. **h** Confocal (bar, 5 μm) and STED (bar, 2 μm) images of cross-sections of transfected muscles stained with the indicated antibodies. n = two independent experiments. STED analysis was performed using the spots module of the Imaris software for β-dystroglycan and insulin receptor (white and red spheres, respectively). β-Dystroglycan-insulin receptor co-occurrence is in blue. **i** Proximity ligation assay (PLA) was performed on cross-sections of transfected muscles stained with β-dystroglycan and insulin receptor antibodies. Red fluorescent dots indicate areas of β-dystroglycan-insulin receptor association.
underestimate the actual effects of plakoglobin downregulation because only about 70% of the fibers were transfected (Supplementary Fig. 4b).

As expected from the fall in P13K-Akt signaling, in the muscles expressing shJUP atrophy became evident because the mean TA weights was lower by 20% than control (Fig. 3e), and the mean cross-sectional area of 500 fibers expressing shJUP was smaller than 500 non-transfected ones (Fig. 3f)\(^21\). Finally, immunofluorescence staining using confocal (Fig. 3g) and STED (Fig. 3h) microscopy, as well as PLA (Fig. 3i), confirmed insulin receptor-β-dystroglycan potential colocalization and association on the sarcolemma of non-transfected or shLacz-expressing fibers, which was markedly reduced in fibers expressing shJUP (Fig. 3g–i). Therefore, plakoglobin is required for DGC stability, which appears to be linked to normal signaling through the insulin receptor.

### Inhibition of insulin receptor function reduces association with DGC.

Altogether, these observations suggested that DGC integrity is linked to insulin receptor activity via plakoglobin. To test this idea and investigate whether the membrane content of DGC is influenced by the fall in P13K-Akt signaling, we used transgenic mouse (MKR) model for type 2 diabetes, which express

\[\text{Inhibition of insulin receptor function reduces association with DGC.}\]

Therefore, plakoglobin is required for DGC stability, which appears to be linked to normal signaling through the insulin receptor.

Plakoglobin prevents DGC-insulin receptor loss in disease.

These observations suggested that increasing the level of plakoglobin in MKR mice muscle should enhance DGC-insulin receptor association, and accentuate insulin signaling. Accordingly, plakoglobin-DGC-insulin receptor heteromultimers were compromised and P13K-Akt signaling fell in muscles from MKR mice compared with WT, but not when 6His-plakoglobin was overexpressed (Fig. 5a, b). Interestingly, in MKR mouse muscles, glycosylated β-dystroglycan remained bound to plakoglobin (Fig. 5b, lanes 5–7), suggesting an altered distribution of β-dystroglycan on the membrane when its association with the insulin receptor and other DGC components is low. This beneficial effect of plakoglobin overexpression did not require the function of its close homolog, β-catenin, because in the MKR mouse muscles expressing 6His-tagged plakoglobin, the simultaneous downregulation of β-catenin with shRNA (shCTNNB1) (Fig. 5c) did not perturb plakoglobin-DGC-insulin receptor association (Fig. 5d, e). Plakoglobin overexpression also enhanced glucose uptake by MKR mouse muscles (Fig. 5f) (cytochalasin B is a cell-permeable mycotoxin that competitively inhibits glucose transport into cells, and was used here to evaluate specifically regulated glucose uptake\(^49\), and markedly attenuated muscle fiber atrophy (Fig. 5g).

In light of these findings in MKR mouse muscles, we investigated whether loss of DGC integrity in muscles from \(mdx\) mice influences insulin signaling, and the role of plakoglobin. In muscles from \(mdx\) mice, dystrophin was absent and β-dystroglycan was reduced compared with WT (Fig. 5h). Consistent with our findings above in MKR mouse muscles, the membrane content of glycosylated β-dystroglycan-plakoglobin-insulin receptor in \(mdx\) mice was lower than WT, but not when plakoglobin was overexpressed (Fig. 5i). Thus, plakoglobin regulates muscle size by linking insulin receptor activity to DGC integrity.

### DGC-insulin receptor-plakoglobin interaction domain mapping.

Co-assembly of DGC, the insulin receptor, and plakoglobin was demonstrated by mapping the sites on plakoglobin that constitute their interaction. Plakoglobin is composed of an N-terminal head domain, a C-terminal tail domain, and a central conserved domain containing 12 armadillo repeats\(^41\). Mutations within the N-terminal domain reduce plakoglobin membrane localization and cause cardiomyopathy in human\(^42\), and deletion of the C-terminal domain causes Naxos disease\(^33, 44\). To identify
the critical domains in plakoglobin that are required for its heterodimerization with DGC and the insulin receptor, we generated 6His-V5-tagged truncation mutants of plakoglobin lacking the N-terminal (ΔN), the C-terminal (ΔC), or either end (ΔNC) domains, while leaving the central armadillo domain intact (Supplementary Fig. 6a). Overexpression of ΔN-plakoglobin in normal muscle for 6 days resulted in decreased insulin receptor phosphorylation compared with muscles expressing full-length (FL) plakoglobin (Supplementary Fig. 6b), strongly suggesting that the plakoglobin N terminus is required for interaction with and
activation of the insulin receptor. Consistently, affinity purification of plakoglobin truncation mutants from transfected muscles using Nickel column and histidine gradient (Supplementary Fig. 6c), and subsequent densitometric measurement of protein ratios indicated that deletion of plakoglobin N terminus (ΔN) reduced its association only with the insulin receptor, but not with β-dystroglycan or dystrophin, compared with FL-plakoglobin (Supplementary Fig. 6d). By contrast, plakoglobin-ΔC, which promotes formation of large abnormal membrane structures in Naxos disease43,44, showed increased association with both the insulin receptor and β-dystroglycan, and compensated for the loss of plakoglobin N terminus in plakoglobin-ΔNC, which remained bound to the insulin receptor (Supplementary Fig. 6d). These interactions were specific because none of these proteins bound the Nickel column in control muscles expressing shLacZ (Supplementary Fig. 6c). Therefore, insulin receptor interacts with plakoglobin N terminus, and β-dystroglycan binds to sites adjacent to this region, which seem to be regulated by plakoglobin C-terminal tail. Interestingly, dystrophin bound similarly to FL-plakoglobin and all truncation mutants (Supplementary Fig. 6d), suggesting that its binding sites are located within plakoglobin central armadillo repeats domain. Plakoglobin may serve a scaffold linking DGC and insulin receptors physically and functionally to maintain muscle mass.

**Fig. 4 In MKR mouse muscles insulin receptor-DGC association is reduced.** a Mean body (n = 5) and TA (n = 12) weights of MKR mice at 8 weeks old are presented as percentage of WT. *P < 0.05, by one-tailed t test. Data are mean ± SEM. n = two independent experiments. b Left: Laminin staining (white). Bar, 50 μm. Right: Cross-sectional areas of 834 fibers from WT (black bars) and MKR (gray bars) mice. n = 3 mice. c Left: Soluble fractions of mouse muscles injected with saline or glucose were analyzed by immunoblotting. n = two independent experiments. Right: Densitometric measurement of presented blots. d Insulin receptor immunoprecipitation from muscle membranes of mice injected with saline or glucose. n = two independent experiments. e, f High MW protein peak fractions isolated from mouse muscles were analyzed by silver staining and immunoblotting. n = three independent experiments. g Membrane-actin fractions from mouse muscles were analyzed by glycerol gradients. Red triangle marks fractions containing glycosylated-β-dystroglycan in WT. n = two independent experiments. h Isolated mouse muscle membranes were analyzed by glycerol gradients. n = two independent experiments. Red triangle marks fractions containing glycosylated-β-dystroglycan in WT. i Top: Muscle insoluble fractions were analyzed by immunoblotting. n = two independent experiments. Bottom: Densitometric measurement of presented blots. j Top: Muscle cross-sections were stained with plakoglobin, β-dystroglycan, and insulin receptor antibodies. Bar, 20 μm. n = three independent experiments. Middle: Fluorescence intensity was quantified using the Imaris software. Bottom: Colocalization of indicated proteins in region of interest (region of co-occurrence, data are ratio to WT), and the corresponding Pearson’s correlation coefficients of colocalization. n = 6, and two independent experiments. *P < 0.05 and **P < 0.005 vs. WT, by one-tailed t test. Data are mean ± SEM. k STED: Stimulated emission depletion microscopy. Confocal (bar, 5 μm) and STED (bar, 2 μm) images of muscles cross-sections stained with indicated antibodies. n = two independent experiments. STED analysis was performed using the spots module of Imaris software for the three proteins. The double and triple co-occurrence spots are presented in yellow (plakoglobin-β-dystroglycan) and blue (plakoglobin-β-dystroglycan-insulin receptor). l Proximity ligation assay (PLA) was performed on muscle cross-sections stained with β-dystroglycan and insulin receptor antibodies. Red fluorescent dots (left) and blue dot analysis (right) indicate areas of β-dystroglycan-insulin receptor association.

**Plakoglobin prevents DGC-insulin receptor loss by autophagy.** Previously we have shown that plakoglobin overexpression during fasting leads to a greater activity of the insulin receptor and PI3K-Akt-FoxO signaling21, and here we demonstrate that these effects result from stabilization of DGC-insulin receptor assemblies on the plasma membrane (Fig. 6c, d and Supplementary Fig. 7a), indicating that during fasting these proteins are probably lost by the lysosome. Accordingly, the potential colocalization of plakoglobin, insulin receptor, and β-dystroglycan with the lysosomal marker LAMP1 increased during fasting (Supplementary Fig. 7c, d). Interestingly, plakoglobin levels did not increase on the membrane following colchicine injection (Fig. 6d), suggesting that this protein is not degraded but rather accumulates inside the muscle fiber (Fig. 6a), probably bound to autophagic vesicles containing β-dystroglycan and insulin receptor.

**Dynamics of plakoglobin-DGC-insulin receptor association.** Together, signal transduction through the insulin receptor is initiated at these, DGC-rich, protein clusters on the plasma membrane. Therefore, DGC-insulin receptor coupling must be tightly regulated to prevent inappropriate activation of PI3K-Akt-FoxO signaling and excessive tissue growth, and to efficiently terminate transmission of growth signals from cell surface receptors when cellular energy charge is low. To determine the dynamics of these interactions, we studied mouse muscles during the physiological adaptation to fasting, where blood glucose and insulin levels are low and consequently signaling through the insulin receptor is reduced in all tissues. Immunofluorescence and biochemical analyses showed that the membrane content of plakoglobin, β-dystroglycan, and insulin receptors was reduced during fasting (Fig. 6a, b and Supplementary Fig. 7a). Plakoglobin immunoprecipitation from membrane extracts indicated reduced association with β-dystroglycan during fasting (Fig. 6c, graph), while plakoglobin-insulin receptor association remained intact (Fig. 6c)21. Colchicine injection of mice to perturb microtubule polymerization and inhibit autophagy flux (Supplementary Fig. 7b)45,46 attenuated this response to fasting, and plakoglobin-insulin receptor-β-dystroglycan-dystrophin co-assemblies accumulated on the muscle membrane (Fig. 6c, d and Supplementary Fig. 7a), indicating that during fasting these proteins are probably lost by the lysosome. Accordingly, the potential colocalization of plakoglobin, insulin receptor, and β-dystroglycan with the lysosomal marker LAMP1 increased during fasting (Supplementary Fig. 7c, d). Interestingly, plakoglobin levels did not increase on the membrane following colchicine injection (Fig. 6d), suggesting that this protein is not degraded but rather accumulates inside the muscle fiber (Fig. 6a), probably bound to autophagic vesicles containing β-dystroglycan and insulin receptor.
of this mutation on colocalization with plakoglobin, insulin receptor, and LC3 during fasting. Following electroporation into muscles, GFP-β-dystroglycan and GFP-β-dystroglycan-ΔLIR showed a similar distribution as did the endogenous protein on the plane of the muscle membrane (Fig. 6h), although GFP-β- dystroglycan-ΔLIR also accumulated inside the muscle fiber probably because the deletion of LIR domain and failure to bind LC3 stabilized this protein. In addition, β-dystroglycan’s LIR domain may be important for association with plakoglobin on the muscle membrane. In fact, the potential colocalization of GFP-β-dystroglycan-ΔLIR with LC3, plakoglobin, and the insulin receptor decreased markedly compared to GFP-tagged FL-β-dystroglycan (Fig. 6h), indicating that β-dystroglycan’s LIR domain is required for stabilization of plakoglobin-DGC-insulin receptor assembly on the muscle membrane (i.e., through association with plakoglobin (Fig. 6g)), and for binding to
LC3 when autophagy is induced and plakoglobin-DGC-insulin receptor clusters are lost. It is noteworthy that the overexpressed GFP-β-dystroglycan may colocalize with endogenous insulin receptor and plakoglobin proteins in different proportions, as indicated by the depression of Pearson’s correlation coefficients (PCCs), as often occurs with overexpressed proteins) (Fig. 6h). Thus, under normal conditions, when plakoglobin-DGC-insulin receptor co-assembly is intact, plakoglobin seems to protect
**Fig. 6 Plakoglobin-DGC-insulin receptor association is regulated by autophagy.** Muscles from fed and fasted (2 days) mice are analyzed. Data are mean ± SEM. P values by one-tailed t test. Fluorescence intensity was obtained using the Imaris software. a Top: Muscle cross-sections stained with indicated antibodies. Bar, 20 μm. n = four independent experiments. Bottom: Fluorescence intensity. n = 4. *P < 0.05 vs. fed. b Equal membrane extracts from muscles were analyzed by immunoblotting. n = two independent experiments. c Left: Plakoglobin immunoprecipitation from muscle membranes from mice treated with colchicine or vehicle was analyzed by immunoblotting. n = two independent experiments. Right: Densitometric measurement of presented blots. d Left: Muscle cross-sections from fasted mice treated with colchicine or vehicle were stained with indicated antibodies. Bar, 20 μm. n = three independent experiments. Right: Fluorescence intensity. n = 3. *P < 0.05 vs. vehicle injection. e Membranes purified from muscles expressing shLacz or 6His-plakoglobin were analyzed by glycerol gradients and immunoblot. Red rectangle marks fractions containing glycosylated-β-dystroglycan in shLacz-expressing muscles. n = four independent experiments. f In vitro competition assay: plakoglobin immunoprecipitation from membrane extracts from muscles of fed mice, followed by incubation in vitro with synthetic peptides corresponding to β-dystroglycan’s-LIR domains or scrambled control. β-Dystroglycan LIR-2 peptide efficiently competed with β-dystroglycan on binding to plakoglobin. Right: Densitometric measurement, β-dystroglycan to plakoglobin ratio in protein precipitates following incubation with synthetic peptides. n = four independent experiments. *P < 0.05 vs. scrambled. g Left: In vitro competition assay: plakoglobin immunoprecipitation from membrane extracts from muscles of fasted mice, followed by incubation in vitro with synthetic peptides corresponding to β-dystroglycan’s-LIR domains or scrambled control. β-Dystroglycan LIR-2 peptide efficiently competed with β-dystroglycan on binding to plakoglobin. Right: Densitometric measurement, β-dystroglycan to plakoglobin ratio in protein precipitates following incubation with synthetic peptides. n = four independent experiments. *P < 0.05 vs. scrambled. h Proposed model: Under normal conditions, basal recycling of plakoglobin-DGC-insulin receptor co-assemblies occurs via plakoglobin masking β-dystroglycan LIR domains. During fasting, when autophagy is induced, LC3 competes with plakoglobin on binding to β-dystroglycan’s LIR domains, directing the formed vesicles to the lysosome.
β-dystroglycan-insulin receptor co-assembly from LC3-mediated degradation by masking β-dystroglycan LIR domains.

**Discussion**

These studies have uncovered protein assemblies of insulin receptors and DGC, whose structural integrity and functional properties are linked and endowed by plakoglobin. We show that plakoglobin stabilizes these structural and signaling modules at costameres, and contributes to maintenance of cell size by promoting tissue integrity through desmin-DGC-laminin axis, and simultaneously regulating signaling through the insulin receptor. Plakoglobin’s stimulation of insulin signaling seems to result from it promoting a tight assembly between the insulin receptor and DGC because decreasing plakoglobin levels in normal muscle reduced DGC-insulin receptor association and insulin signaling, whereas increasing plakoglobin content in diabetic or mdx mice muscles enhanced DGC-insulin receptor co-assembly. Consequently, DGC acts as a cellular signaling node containing plakoglobin as a pivotal subunit, and perturbation of plakoglobin function (e.g., by Trim32)21 probably contributes to the insulin resistance seen in various catabolic states (e.g., untreated diabetes, obesity).

Previous studies demonstrated a correlation between impaired insulin signaling, DGC dissociation, and muscle loss12,14,15,48, which can now be explained based on our findings that DGC integrity is linked to insulin receptor activity. For example, reduced sensitivity to insulin is seen in some DMD and Becker muscular dystrophy human patients7,8,49, and insulin-related metabolic disorders (e.g., hyperinsulinemia, glucose intolerance, obesity) are seen in muscular dystrophies such as myotonic dystrophy type I and 249–51. Similarly, during aging, DGC dissociation significantly contributes to the deterioration in muscle size, strength, and function52, which often correlates with the development of insulin resistance53,54. In addition, muscle atrophy due to denervation, as occurs during aging, appears to alter muscle sensitivity to insulin37,55,56.

Our findings of DGC as a signaling hub are surprising because there had been no prior reports linking the insulin receptor and DGC functionally or structurally. Clustering of signaling receptors in membrane domains is necessary for ligand-dependent signal transmission57, and our findings here predict such clustering may occur via association with tissue structural modules. These signaling hubs probably dynamically disassemble and reassemble in response to external cues in a changing environment57. Accordingly, we show that stimulation of insulin secretion by the injection of glucose enhances DGC-insulin receptor association and accumulation on the plasma membrane (Fig. 3b, c), whereas reduced signaling through the insulin receptor, as occurs during fasting or diabetes, leads to a fall in the membrane content of these protein assemblies (Figs. 4, 6, and Supplementary Fig. 7a). Plakoglobin stabilizes these heteromultimers on the plasma membrane to maintain tissue integrity because its downregulation (by shU6) in normal muscle reduced the membrane content of plakoglobin-DGC-insulin receptor co-assemblies and caused atrophy (Fig. 3), and increasing plakoglobin levels in fasting or diabetes stabilized these protein clusters on the muscle membrane and attenuated atrophy (Figs. 5 and 6e). These changes in plakoglobin levels also influence the levels of glycosylated β-dystroglycan (Fig. 3a–c and Supplementary Fig. 4a), whose presence on the plasma membrane is essential for DGC stability11.

Here, we report a mechanism that dynamically regulates the engagement of these DGC-rich signaling clusters on the muscle membrane. Under normal conditions, when growth or survival signals are transmitted and insulin/IGF-I-Pi3K-Akt pathway is active and inhibits proteolysis by autophagy22,23,38,59, there is a basal recycling of plakoglobin-DGC-insulin receptor co-assemblies, and plakoglobin prevents their loss by masking β-dystroglycan’s LIR domains. However, during fasting and in diseased states, when IGF-I and insulin levels are low, LC3 levels rise and autophagy is induced23,38,60. LC3 competes with plakoglobin on binding to β-dystroglycan, and through association with β-dystroglycan’s LIR domains directs the recycling plakoglobin-DGC-insulin receptor-containing vesicles to the lysosome61. Consistently, in MKR mouse muscles, impaired insulin receptor activity led to a prominent reduction in the amounts of plakoglobin and DGC components on the membrane (Fig. 4), which probably resulted from accelerated degradation because these proteins did not accumulate in the cytosol and their gene expression was similar in muscles from MKR mice and WT controls (Supplementary Fig. 5a, b). Increasing plakoglobin content (by overexpression) stabilizes DGC-insulin receptor association on the membrane probably by surpassing certain inhibitory effects that prevent engagement of these DGC-rich clusters within membrane domains (e.g., LC3). As a result, the cellular response to insulin is accentuated leading to enhanced protein synthesis and glucose uptake, and reduced protein degradation and autophagy (Fig. 5). Because plakoglobin is expressed in all cells, and since similar interactions were demonstrated in the heart and liver (Supplementary Fig. 2), these functions of plakoglobin are probably general to many tissues.

Therefore, a reciprocal regulation of DGC and the insulin receptor seems to be required to promote DGC stability and insulin receptor activity. β-Dystroglycan probably functions as a scaffold for the insulin receptor as it does for acetylcholine receptor during the formation of neuromuscular junctions in development62, and as a signaling hub maintaining insulin receptor activity. In turn, active insulin receptor seems to stabilize the DGC by inhibiting degradation of its constituents via autophagy. Plakoglobin may serve as scaffold protein at the sarcolemma, where the insulin receptor is positioned to interact with the DGC. Here we show that insulin receptors interact with plakoglobin N terminus and β-dystroglycan recognizes adjacent domains, which seem to be masked by plakoglobin C-terminal region43,63. Deletion of plakoglobin’s C-terminal domain causes Naxos disease and leads to the formation of large abnormal cadherin-based membrane structures, suggesting that this domain limits the size of membrane structures and regulates protein–protein interactions required for their assembly43,44. Consistently, we demonstrate that overexpression of plakoglobin ΔC mutant enhances association with the DGC and the insulin receptor on the plasma membrane, albeit with no significant effect on insulin receptor activity (Fig. 6). In knock-in mice expressing plakoglobin-ΔC, cardiac function is normal suggesting that this carboxy-terminal domain is dispensable for plakoglobin function in the heart64. The effects of this mutation on plakoglobin function and its role in cardiomyopathies merit in-depth study based on the present identification of the protein complexes that plakoglobin forms, and its physiological roles.

In the heart and epithelia, plakoglobin links desmin filaments to desmosomes via desmoplakin33,34,65. Skeletal muscle lacks “classie” desmosomes, but contains desmosomal components, which are present on the muscle membrane and can be isolated together with plakoglobin, DGC, and insulin signaling components (Supplementary Table 1)21. Unlike β-dystroglycan, plakoglobin is not evenly distributed along the sarcolemma, and instead accumulates in discrete regions by binding to specific receptors to stimulate signaling pathways and to promote cell–ECM contacts as proposed here. These regions are located in close proximity to the nucleus, probably to efficiently translate extracellular signals to transcriptional response. Furthermore, these clusters of plakoglobin-DGC-insulin receptor contain vinculin, which in the skeletal muscle is confined to costameres that link the desmin cytoskeleton and the bound contractile apparatus to laminin at the ECM, hence
contributing to muscle mechanical integrity. In fact, the strongest evidence for the importance of plakoglobin to desmin filament stability and thus tissue architecture were our findings that in normal muscle plakoglobin downregulation alone was sufficient to promote desmin depolymerization and atrophy (Fig. 3d–f). Whether loss of intact desmin filaments in skeletal muscle, as occurs in desmin myopathies, affects DGC integrity or signal transmission via the insulin receptor, and whether plakoglobin cellular distribution changes in these diseases are important questions for future research.

Plakoglobin may mediate growth-promoting signals also via the IGF-1-R, although plakoglobin’s beneficial effects on insulin signaling seem to result primarily from it acting on the insulin receptor because in MKR mouse muscles lacking functional IGF-1-R, although plakoglobin promotes desmin depolymerization and atrophy (Fig. 3d). Lower limb mouse skeletal muscles (1g) were homogenized in 19 volumes of cold buffer A (20 mM Tris, pH 7.2, 100 mM KCl, 5 mM EGTA, 40 mM imidazole, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 mM benzamidine, 10 μg/ml leupeptin, 50 mM NaF, 2.7 mM sodium orthovanadate, and 1% Triton X-100). For fiber size analysis, cross-sections of muscles were fixed in 4% PFA and fiber membrane was stained with laminin antibody (see details under immunofluorescence). Cross-sectional areas of at least 300 transsected fibers (expressing GFP) and 500 adjacent non-transsected ones in the same muscle sample (10 μm) were measured using MetaMorph (Molecular Devices) and Imaris (Bitplane) software. Images were collected using a Nikon Ni-U upright fluorescence microscope with Plan Fluor ×20 0.5NA objective lens and a Hamamatsu C8484-03 cooled CCD camera and MetaMorph software.

**Isolation of native plakoglobin complexes from the muscle.** To isolate plakoglobin-containing complexes from mouse skeletal muscle, we adapted a protocol by Chorev et al. with some modifications. Lower limb mouse skeletal muscles (1g) were homogenized in 19 volumes of cold buffer A (20 mM Tris, pH 7.2, 5 mM EGTA, 100 mM KCl, 1% Triton X-100, 100 μg/ml PMSF, 5 mM benzamidine, 10 μg/ml leupeptin, 50 mM NaF, and 2.7 mM sodium orthovanadate) and centrifuged at 16,000 g for 10 min at 4 °C, the pellet (containing myofilaments, membrane, and cytoskeleton) was washed once in buffer B, and then re-suspended in 10 volumes of (v/v) buffer B (buffer A supplemented with 10 mM ATP) to dissociate myofilibrillar myosin from actin thin filaments. After centrifugation at 16,000 g for 10 min at 4 °C, the supernatant (containing purified membrane-bound and cytoskeletal proteins) was subjected to 30% ammonium sulfate precipitation, and precipitates were centrifuged at 20,000 g for 30 min at 4 °C. The obtained pellet was kept on ice and the supernatant was subjected to an additional 50% ammonium sulfate precipitation. After a final centrifugation at 20,000 g for 30 min at 4 °C, precipitates from 30% and 50% ammonium sulfate precipitations were re-suspended in 600 μl of buffer C (10 mM Tris pH 7.2 and 85% of this suspension (containing whole-cell extract) was collected and stored at −80 °C. The supernatant was subjected to a stepwise ammonium sulfate precipitation, and fractions enriched with plakoglobin (Fig. 1f, lane 7) were analyzed by mass spectrometry, glycerol gradient fractionation, and western blotting.

To identify plakoglobin-binding proteins in whole muscle extracts (Fig. 2a, b), TA muscles from WT mice (200 mg TA from five mice) were electroporated with a plasmid encoding 6His-tagged plakoglobin, and 7 days later, the muscles were dissected, and whole-cell extracts incubated with Ni beads (according to the manufacturer’s instructions) to purify the 6His-tagged plakoglobin and bound proteins. The eluting protein fraction was then used for mass spectrometry, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting.

**Antibodies and constructs.** The plasmids encoding shRNA against plakoglobin and Lacz were cloned into pcDNA 6.2-GW/EmGFP-mRFP vector using Invitrogen’s BLOCK-it RNAi Expression Vector Kit. For generation of GFP–β-dystroglycan–ΔLIR encoding plasmid, a FlII mouse β-dystroglycan encoding pEGFP plasmid (kindly provided by Dr. Winder) served as a template for consecutive mutations of β-dystroglycan’s 864–851 and 714–719 residues by PCR using two primer sets: CCTCTGAGACCCAGACCTGGCTGAGACTGCCAGG and CCAGG together with GCGTTAGGATCCATCTGACCTGAGCAAGAGG, and CTAAGG together with GCGTTAGGATCCATCTGACCTGAGCAAGAGG, respectively. The β-dystroglycan–ΔLIR mutant generated by PCR was cloned into pEGFP vector, and the final construct was verified by nucleotide sequencing.

The construct encoding the 6His-plakoglobin was provided by Dr. Yoshitaka Sekido (Nagoya University School of Medicine, Nagoya, Japan). Plakoglobin antibodies were from: AT3 (Cat# SAB2150100, for immunoprecipitation (1:50) and immunoblotting (1:10000) and Acris (Cat# AP3320SU-01, lot# 610051, for immunofluorescence (1:150)). Anti-dystrophin (Cat# ab15277, lot# GR 250686-2, 1:1000), anti-desmin (Cat# ab5892, 1:1000), anti-vinculin (Cat# ab73412, lot# GR 29133-1, 1:1000), anti-caveolin-1 (Cat# ab2910, lot# GR 235528-4, 1:1000), anti-insulin receptor (Cat# ab5500, lot# GR 242593-6, for immunofluorescence, 1:50), and anti-myosin (Cat# ab7784, 1:1000) were from Abcam. Anti-phospho-insulin receptor (Y1361) (Cat# 3023, lot# 2, 1:1000), anti-insulin receptor (Cat# 3025, lot# 8, for immunoblotting (1:1000) and immunoprecipitation (1:50)), anti-phospho-PEK (Cat# 4228, lot# 2, 1:2000), anti-phospho-AKT (Cat# 2927, lot# 13, 1:1000), anti-Akt (Cat# 2972, lot# 25, 1:1000), and anti-phospho AKT (Cat# 2972, lot# 25, 1:1000) were from Cell Signaling Technologies. The β-dystroglycan antibody developed by Glenn E. Morris (RAF Orthopedic Hospital, Oswestry, UK, 1:100) was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa city, Iowa (Cat# MANDAG2, clone 7D11, lot# 51ea). Phospho-serine antibody was from ECM Biosciences (Cat# PP2251, lot# 5, 1:1000). Anti-laminin (Cat# L9393, lot# 0466837, 1:1000), and anti-GAPDH (Cat# G8795, 1:1000) were from Sigma. Synthorpin antibody (Cat# Sc-50460, lot# F1109, 1:1000), caveolin-3 antibody (Cat# sc-5510, lot# L1714, 1:1000), MuSK antibody (clone N-19, Cat# sc-6010, 1:1000), and V5 antibody (Cat# R960-2546-0705, lot# 1831411, 1:1000) were from Santa Cruz Biotechnology (Cat# sc-3310, lot# L1714).
Glycerol gradient fractionation. Equal amounts of muscle homogenates were layered on a linear 10–40% glycerol gradient containing 20 mM Tris, pH 7.6, 5 mM EDTA, pH 7.5, 100 mM KC1, 1 mM DTT, 0.24% sodium deoxycholate, and 1 mM sodium orthovanadate. Following centrifugation at 131,300 × g for 24 h at 4 °C using a MLS-50 Swinging-Bucket rotor (Beckman Coulter, Brea, CA) to sediment by SDS-PAGE and immunoblotting with specific antibodies. Immunoprecipitation experiments using specific antibodies (control sample contained mouse IgG) were performed overnight at 4 °C, and protein A/G agarose was then added for 4 h. To remove cross-linked and loosely associated proteins, the resulting precipitates were washed extensively with 10 bed volumes of each of the following buffers: buffer A (50 mM Tris-HCl, pH 8, 500 mM NaCl, 0.1% SDS, 0.1% Triton, 5 mM EDTA), buffer B (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% SDS, 0.1% Triton, 5 mM EDTA), and buffer C (50 mM Tris-HCl, pH 8, 0.1% Triton, 5 mM EDTA). Protein precipitates were subjected to protein loading buffer containing 50 mM DTT and were analyzed by immunoblotting.

Protein analysis. For immunoblotting and immunoprecipitation, tissue homogenates and fractions of isolated plakoglobin-containing complexes were resolved by SDS-PAGE and immunoblotting with specific antibodies. Immunoprecipitation experiments using specific antibodies (control sample contained mouse IgG) were performed overnight at 4 °C, and protein A/G agarose was then added for 4 h. To remove cross-linked and loosely associated proteins, the resulting precipitates were washed extensively with 10 bed volumes of each of the following buffers: buffer A (50 mM Tris-HCl, pH 8, 500 mM NaCl, 0.1% SDS, 0.1% Triton, 5 mM EDTA), buffer B (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.1% SDS, 0.1% Triton, 5 mM EDTA), and buffer C (50 mM Tris-HCl, pH 8, 0.1% Triton, 5 mM EDTA). Protein precipitates were subjected to protein loading buffer containing 50 mM DTT and were analyzed by immunoblotting.

Immunofluorescence labeling of frozen muscle sections. Frozen cross-sections of mouse TA were cut at 10 or 30 μm (for Z-stack and 3D modeling), fixed in 4% paraformaldehyde (PFA), and incubated in blocking solution (0.2% bovine serum albumin and 5% normal goat serum in PBS-T) for 1 h at room temperature (RT). Immunofluorescence was performed using plakoglobin (1:50), laminin (1:50), vinculin (1:50), β-dystroglycan (1:30), or insulin receptor (1:30) antibodies overnight at 4 °C, followed by 1 h incubation at RT with secondary antibodies conjugated to Alexa Fluor 568, 647 or DyLight 488 (1:1000). Both primary and secondary antibodies were diluted in blocking solution. Confocal images were collected using a 40× or 63× objective lenses with a Leica SP8 confocal microscope (Zeiss, Oberkochen, Germany) with a Plan-Apochromat ×63 1.4 NA objective lens and BP 593/46, BP 525/50, and 640–797 filters, and Imaris 8.2 software. STEED images were collected using a Leica DMi8 CS Bino super-resolution microscope (TCS SP8 STEED) with a Plan-Apochromat ×100 1.4 NA objective lens, WLL (white light laser, covers the spectral range from 470 to 670 nm) and the Most Versatile Beamsplitter AOB5, and Leica 3 Hyd SP GaAsP-detector. PLA assay was performed in humid chamber according to the manufacturer’s instructions (Duolink in situ Red, through Sigma). Briefly, muscle cross-sections were incubated with β-dystroglycan and insulin receptor antibodies overnight at 4 °C, and the control sample was incubated with β-dystroglycan antibody alone. Following incubation with probe-linked secondary antibodies (1 h at 37 °C), the hybridized complementary probes (those that are within 20–100 nm) were ligated (30 min at 37 °C) to form circular DNA. Finally, rolling circle amplification reaction and incorporation of red fluorescently labeled nucleotides were allowed to proceed for 1 h. Fluorescently labeled DNA and immunolabeled and immunostained images were collected using an inverted LSM 710 laser scanning confocal microscope (Zeiss, Oberkothen, Germany) with a Plan-Apochromat ×63 1.4 NA objective lens and BP 593/46, BP 525/50, and 640–797 filters, and Imaris 8.2 software.

[3H]-2-deoxyglucose uptake by the skeletal muscle. For glucose uptake assay, we used a modified protocol adapted from Fernandez et al., Lauro et al., and Witzaczek et al. 4-Bromobenzoic acid (40 μg/mL) was dissolved in 100% ethanol, and 10 μL/10 mg of muscle was administered for 30 min, and then dissected muscles were homogenized in 100 μL lysis buffer (20 mM Tris, pH 7.4, 5 mM EDTA, 100 mM NaF, 2 mM sodium orthovanadate, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 3 mM benzamidine, and 1 mM PMSF) and rates of [3H]-2-deoxyglucose uptake were determined by scintillation counter. Colocalization (PCC) and percent colocalization in region of interest (is the region of cocurrence) were quantified between signal intensities of β-dystroglycan and plakoglobin, β-dystroglycan and insulin receptor, and plakoglobin and insulin receptor using confocal images, and image analysis was performed with Imaris (Bitplane, ver 9.1.2) by ImarisColoc module. This pixel-based module provided a cut-off threshold for separating signal from background pixels and defined the overlap between any two-color channels (colocalized pixels) of the image. Because PCC values did not reach 1, we conclude that these proteins may colocalize on the plasma membrane.

STED images were collected using a Leica DMi8 CS Bino super-resolution microscope (TCS SP8 STEED) with a Plan-Apochromat ×100 1.4 NA objective lens, WLL (covers the spectral range from 470 to 670 nm) and the Most Versatile Beamsplitter AOB5, and Leica 3 Hyd SP GaAsP-Detector. STEED images were analyzed using the STEED image reconstruction module of Leica. Sub-diffraction spots cocurrence analysis and visualizations were implemented using the Imaris 9.1.2 software (Oxford, Bitplane). IMARIS spots module was set to identify sub-diffraction spots as particles with intensity above 3000 and to reidentify triple spots cocurrence, the insulin receptor staining was used as baseline to filter-in the other proteins beyond intensity threshold value of 1500, and to reﬁne the positioning of the triple particles. Moreover, a built-in Imaris plugin spot cocurrence algorithm (requiring ImarisXT module) was used to identify triple spots centers with maximum distance of 250 nm.

Data availability

The datasets generated and analyzed during the current study, as well as materials and associated protocols, are available from the corresponding author on request. The source data underlying Figs. 1b, d, f, 2b–g, 3a–g, and 4a–j, and Supplementary Figs. 1a, b, 2a–d, 4a–b, d–e, 6d–b, 7a–d are provided as a Source Data file. Accession code availability: the mass spectrometry proteomics data from isolation of plakoglobin-containing protein complexes have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the database identifier PXD016989.

Received: 18 July 2019; Accepted: 4 February 2020; Published online: 13 March 2020

Refereed by
1. Bonaldo, P. & Sandri, M. Cellular and molecular mechanisms of muscle atrophy. Dis. Models Mech. 6, 25–39 (2013).
2. Glass, D. J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974–1984 (2005).
3. DeFronzo, R. A. & Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(Suppl. 2), S157–S163 (2009).

4. Fernandez, A. M. Molecular Function of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15, 1926–1934 (2001).

5. Heyrick, S. J. et al. Defect in skeletal muscle phosphorylidyinositol-3-kinase in obese insulin-resistant mice. J. Clin. Invest. 91, 1358–1366 (1993).

6. Kohn, A. E., Hull, R. L., Jr., & Utschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006).

7. Rodriguez-Cruz, M. et al. Evidence of insulin resistance and other metabolic alterations in boys with duchenne or Becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015).

8. Freidenberg, G. R. & Olefsky, J. M. Dissociation of insulin resistance and decreased insulin receptor binding in Duchenne muscular dystrophy. J. Clin. Invest. 60, 320–327 (1985).

9. Hoffman, E., P. Brown, R. H. Jr, & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Proc. Natl Acad. Sci. USA 88, 1008–1012 (1991).

10. Bassat, E. et al. The extracellular matrix protein agrin promotes heart morphogenesis. Proc. Natl Acad. Sci. USA 101, 12971–12976 (2004).

11. Koenig, M., Monaco, A. P. & Kunkel, L. M. The complete sequence of the dystrophin gene: implications for missense mutations. J. Cell Biol. 113, 1079–1092 (1996).

12. Costantini, B. Dystrophin complex functions as a scaffold for signalling proteins. Biochim. Biophys. Acta 1836, 635–642 (2014).

13. Pardo, J. V., Siliciano, J. D. & Craig, S. W. A vinculin-containing cortical lattice in skeletal muscle: transverse lattice elements (costameres) in sites of attachment between myofilaments and sarcotubules. Proc. Natl Acad. Sci. USA 108, 10012–10017 (2011).

14. Acharya, S. et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421–432 (2005).

15. Galvin, J., Eyermann, C. & Colognato, H. Dystroglycan modulates the ability of insulin-like growth factor-1 to promote oligodendrocyte differentiation. J. Neurosci. Res. 88, 3295–3307 (2010).

16. Bassat, E. et al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature 547, 179–184 (2017).

17. Gumbiner, B. M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 84, 345–357 (1996).

18. Gumbiner, B. M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell. Biol. 6, 622–634 (2005).

19. Jamora, C. & Fuchs, E. Intercellular adhesion, signalling and the cytoskeleton. Nat. Cell Biol. 4, E101–E108 (2002).

20. Calautti, E., Li, J., Sonnella, S., Brissette, J. L. & Goetinck, P. F. Phosphoinositide 3-kinase signalling to Akt promotes keratocystocyte differentiation versus death. J. Biol. Chem. 280, 32856–32865 (2005).

21. Cohen, S., Lee, D., Zhai, B., Gyi, S. P. & Goldberg, A. L. Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 204, 747–758 (2014).

22. Sacheck, J. M., Ohtsuka, A., McLary, S. C. & Goldberg, A. L. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Mol. Pain 4, E101 (2008).

23. Porter, G. A., Dmytrenko, G. M., Winkelmann, J. C. & Bloch, R. J. Dystrophin lattice in skeletal muscle: transverse lattice elements (costameres) and related ubiquitin ligases, atrogin-1 and MuRF1. J. Cell Sci. 120, 159–169 (2007).

24. Porter, G. A., Rice, K. M., Preston, D. L., Neff, D., Norton, M. & Blough, E. R. Age-related dystrophin-glycoprotein complex structure and function in the rat extensor digitorum longus and soleus muscle. J. Gerontol. A 61, 1119–1129 (2006).

25. Carvalho, C. R. et al. Effect of aging on insulin receptor, insulin receptor substrate-1, and phosphorylidyinositol-3-kinase in liver and muscle of rats. Endocrinology 137, 151–159 (1996).

26. Li, M., Li, C. & Parkhouse, W. S. Age-related differences in the des IGF-1-mediated activation of Akt-1 and p70 S6k in mouse skeletal muscle. Mech. Ageing Dev. 124, 771–778 (2003).

27. Frostick, S. P. The physiological and metabolic consequences of muscle denervation. Int. J. Angiol. 14, 278–287 (1995).

28. Davis, T. & Karl, I. E. Resistance of protein and glucose metabolism to insulin in denervated rat muscle. Biochem. J. 254, 667–675 (1988).

29. Bunnell, S. C. et al. T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. doi:10.1083/jcb.200203043 (2002).

30. Zhao, J. et al. FoxO3 coordinately activates protein degradation by the autophagic lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 6, 472–483 (2007).
59. Stitt, T. N. et al. The IGF-1/P13K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14, 395–403 (2004).

60. Sandri, M. et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399–412 (2004).

61. Birgisdottir, Å. B. et al. The LIR motif—crucial for selective autophagy. J. Cell Biol. https://doi.org/10.1083/jcb.20030808 (2003).

62. Zhang, Z. et al. Normalization of Naxos plakoglobin levels restores cardiac function in mice. J. Clin. Invest. 125, 1708–1712 (2015).

63. Kowalczyk, A. P. et al. The amino-terminal domain of desmoplakin binds to plakoglobin and clusters desmosomal cadherin-plakoglobin complexes. J. Cell Biol. 139, 773–784 (1997).

64. Langenbach, K. J. & Rando, T. A. Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 26, 644–653 (2002).

65. Chen, Y.-J. et al. Direct interaction of β-dystroglycan with F-actin. Biochem. J. https://doi.org/10.1042/bj20030808 (2003).

66. Lauro, D. et al. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat. Genet. 20, 294–298 (1998).

67. Hinkley, J. M. et al. Constitutively active CaMKalpha stimulates skeletal muscle glucose uptake in insulin resistant mice in vivo. Diabetes https://doi.org/10.2337/db13-0452 (2013).

Acknowledgements
This project was supported by grants from the Israel Science Foundation (grant no. 623/15) and the Niedersachsen-Deutsche (grant no. ZN3008) to S. Cohen. Additional funds have been received from The Russell Berrie Nanotechnology Institute, Technion. We thank Prof. Derek Leroith from Rambam medical center for kindly sharing the mdx mice with us, and ART BioScience Ltd for providing mdx mice muscles. We also thank Dr. Dror Chorev and Prof. Michal Sharon from Weizmann institute for their assistance with the protocol for the tandem native purification approach. We are grateful for the kind assistance we received from Dr. Carol Witczak with the glucose uptake approach. We acknowledge the Smoler Proteomics Center at the Technion for their assistance with the proteomics work, the LS&E infrastructure unit for their help with the confocal microscopy, and the microscopy center at Bar Ilan University (Ramat-Gan and Safed) for their assistance with the super-resolution STED microscopy.

Author contributions
Y.E.M. performed all experiments. D.A. prepared all figures. Y.E.M., D.A., and S.C. designed experiments and analyzed data. A.P. generated the constructs presented in Fig. 6 and Supplementary Fig. 6, and helped with confocal microscopy. A.V. performed experiments presented in Fig. 6a and Supplementary Fig. 7a, c. d. B.A. helped with fiber size analysis. N.D. helped with STEM data analysis. Y.M.E. wrote figure legends and Methods section. S.C. wrote the paper.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-14895-9.

Correspondence and requests for materials should be addressed to S.C.

Peer review information Nature Communications thanks Marco Sandri and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020